Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARCH: VIR-2218, VIR-3434, and/or PEG-IFNα in Chronic Hepatitis B
NCT04856085Phase 2Completed
- Sponsor
- Vir Biotechnology
- Start
- Jul 2021
- Primary completion
- Mar 2026
- Modality
- Conjugated siRNA, Monoclonal Antibodies, Chemically Modified siRNA
- Countries
- 12
01
Overview
A Phase 2 trial of elebsiran, tobevibart in Chronic Hepatitis B (CHB), sponsored by Vir Biotechnology. Started Jul 2021; status: completed.
02
Drugs
elebsirantobevibart
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04856085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856085.